Rifampin was glycosylated by a pathogenic species of Nocardia, i.e., Nocardia brasiliensis. The structures of two glycosylated compounds (RIP-1 and RIP-2) isolated from the culture broth of the bacterium were Rifamycins are members of the naphthalenic ansamycin group of antibiotics characterized by a 17-membered ansa chain (1, 5, 11, 17 (Becton Dickinson, Cockeysville, Md.). One loopful of spores or mycelial fragments from the slant cultures of Nocardia spp. was inoculated into a 10-ml Erlenmeyer shake flask containing 5 ml of a seed medium (2% glucose-enriched brain heart infusion medium; Difco Laboratories, Detroit, Mich.) with 4-mm glass beads intended to reduce aggregation of the nocardial cells (21). The inoculated flasks were shaken at 250 rpm (5.8-cm stroke) for 4 days at 27°C. The mature seed cultures were used as inocula for the inactivation or MIC experiments. Other bacterial inocula were prepared by the method previously described (21).
Rifamycins are members of the naphthalenic ansamycin group of antibiotics characterized by a 17-membered ansa chain (1, 5, 11, 17) . Tolypomycin Y, halomicin B, and streptovaricin A belong to this group (11) . A vast number of chemical modifications to the structures of the rifamycins have been made to obtain substances possessing greater activity. Consequently, rifampin ( Fig. 1) , which is now used as a valuable chemotherapeutic agent, was introduced (2, 3, 6) . Rifampin has activity against a great variety of organisms, such as bacteria, viruses, and eukaryotes. It is one of the principal agents used to combat tuberculosis (5, 9, 14) . The antimicrobial activity of rifampin against bacteria is due to its inhibition of DNA-dependent RNA polymerase (2) . Most rifampin-resistant bacteria have been reported to have an alteration in 1-subunits of DNA-dependent RNA polymerase (13) . Contribution of such a resistance mechanism has been reported in the in vitro-developed mutant of Mycobacterium smegmatis and Mycobacterium tuberculosis (18) . In 1987, Dabbs (7) suggested the existence of a new rifampin resistance mechanism, i.e., an inactivation enzyme in Rhodococcus spp., but no detailed chemical studies of the inactivation products were reported then (7) . Quite recently Andersen and Dabbs (1) various time intervals and filtered through a Whatman glass disk filter (GF/C2) with suction. After the mycelia on the filter were washed with cold distilled water, they were dried in an oven at 120°C to ensure a constant weight.
Large-scale preparation of the inactivation products. For large-scale preparation of the inactivation products, the described seed culture was used as an inoculum. The seed culture was inoculated into 100-ml shake flasks at a 2% rate. After 24 h of incubation at 30°C, rifampin was added to a final concentration of 400 ,g/ml and the mixture was incubated for 2 days. After separation from the mycelia by centrifugation at 6,000 rpm (5,800 x g), the supernatant (ca. 50 N. nova and N. farcinica were for the most part resistant, there were a few susceptible strains of these species detected. On the other hand, the MICs of rifampin for N. asteroides ranged from >400 ,ug/ml to less than 0.39 ,ug/ml. The metabolic fate of added rifampin was studied to determine its possible role in the resistance mechanism. One hundred sixty strains of Nocardia were incubated with rifampin, and inactivation was followed by N. asteroides 29/37 9 (7) 3 (2) 4 (2) 6 (6) 4 (3) 2 (2) 6 (6) 1 (1) Table 1 , most of the nocardial strains were found to inactivate rifampin, but such inactivation was not confirmed in susceptible strains requiring MICs of <1.25 ,ug/ml. Interestingly, there were several exceptional strains even among the resistant strains (MIC > 100 p,g/ml) showing no inactivation activity.
N. brasiliensis IFM 0236, which required the highest MICs, was selected to further analyze the inactivation mechanism. In these studies, the time course of rifampin inactivation was determined. As shown in Fig. 2 , when 20 ±g of rifampin per ml was added to the culture medium, rifampin activity diminished within 20 h, and when 200 p,g of rifampin per ml was used, 50 h was required to inactivate the antibiotic. In both experiments, the growth was inhibited in the presence of rifampin, but as rifampin inactivation progressed, growth began. When the inactivation process was monitored by TLC plates, new inactivation products, designated RIP-1 and RIP-2, were observed. The TLC R values of RIP-1 and RIP-2 when developed with CHCl3-Me6H (4:1) were 0.12 and 0.31, respectively (Fig. 3) . The new products were purified by the isolation method described in Materials and Methods. Finally, RIP-1 and RIP-2 were obtained as pure compounds. Since the purified compounds showed the same TLC Rf values in various developing solvents (data not shown), they were considered to be identical to the inactivation products initially recognized and their structures were investigated.
Structure elucidation of RIP-1 and RIP-2. The structures of RIP-1 and RIP-2 were determined spectroscopically by comparison with the data for rifampin obtained with a standard specimen and the reported assignments for rifampin (14) and for rifamycin S (8). The molecular formulae were determined by high-resolution fast-atom bombardment mass spectrometry to be C44H57NO18 for RIP-1 (Na+ adduct ion, mlz 910.3518; calculated for CQ4H57NO18Na [ glucose. No other significant differences were observed between the NMR spectra of RIP-1 and rifampin, which indicates that the rest of the structures of these two compounds are the same. The molecular formula of RIP-2 suggested that it is a monoglycosylated rifampin. Antimicrobial activity of RIP-1 and RIP-2. The antimicrobial activities of purified RIP-1 and RIP-2 were compared with that of rifampin ( Table 2 ). All Nocardia species tested were resistant to RIP-1 and RIP-2, and their MICs against Nocardia were > 100 ,ug/ml. Antimicrobial activities of RIP-1 and RIP-2 against other bacteria, such as Staphylococcus aureus IFM 2014, Micrococcus luteus IFM 2066, Mycobacterium sp. strain 607, and Rhodococcus bronchialis IFM 0150, were >50 ,ug/ml. These results indicated that rifampin was inactivated by the glycosylation of the 23-hydroxyl group. No significant differences in the activities of RIP-1 and RIP-2 were observed.
DISCUSSION
Inactivating enzymes such as ,B-lactamase, acetyltransferase, phosphotransferase, adenyltransferase, and rRNA methylase have been demonstrated as antibiotic resistance mechanisms in pathogenic bacteria (4, 9, 10) . Although there are many reports regarding microbial resistance to rifampin, only a single mechanism based on a mutational alteration of the target enzyme moiety, i.e., DNA-dependent RNA polymerase, has been investigated thoroughly (13, 18) . However, Dabbs (7) and Andersen and Dabbs (1) suggested the existence of another inactivation mechanism for rifamycin on the basis of the following experimental data: (i) the disappearance of the 474-nm peak and (ii) a modest increase in adsorption at shorter wavelengths between 400 and 450 nm in the UV spectra of the inactivation compound (7) . On the basis of the change in its UV absorption spectrum, Dabbs' report (7) suggested that this inactivation compound resulted from modifications in the skeleton of rifampin. No such changes were detected in the UV spectra of RIP-1 and RIP-2; therefore, RIP-1 and RIP-2 seem to be different from the inactivation product reported by Dabbs (7) .
Another example of resistance relating to the glycosylation of an antibiotic has been reported. Recently, a new glycosylated compound, 2'-(O-[P-D-glucopyranosyl])-erythromycin, was isolated from the culture broth of Streptomyces vendargensis (10) . However, it is not clear whether this example is relevant to drug resistance in pathogens, since S. vendargensis is not a pathogenic bacterium. Therefore, to our knowledge, ours is the first report demonstrating the existence of microbial glycosylation of antibiotics as a mechanism important to resistance of pathogenic bacteria.
Nocardia mediterranea is known to be a producer of rifamycin but was recently transferred to a new taxon, Amycolatopsis mediterranei (12) . Despite its transfer to the new genus, it is closely related to Nocardia spp. in various aspects of its physiological and biochemical nature. It has been suggested that resistance genes of pathogenic bacteria may originate from antibiotic-producing microorganisms (4). It has been suggested also that there may be close similarity between the resistance of a producing organism to its own antibiotics and such resistance in pathogenic bacteria (4) . Therefore, the present inactivation of rifampin may be correlated to rifamycin biosynthesis.
We were recently able to purify two different inactivation compounds from N. otitidiscaviarum. Structural studies of these compounds are in progress in our laboratory, and the results will be presented elsewhere. We also have observed a similar inactivation phenomenon in N. asteroides, N. nova, and N. farcinica; however, we did not succeed in isolating inactivation compounds from these species. The reason may have been related to the decomposition of rifampin. On the basis of the reported experiments, we propose that the ability to modify rifampin may be ubiquitous among the nocardioform microorganisms.
The contribution of altered RNA polymerase subunits to rifampin resistance in mycobacteria has been confirmed by many researchers (17) , but the role of such alteration in Nocardia spp. remains obscure. Since pathogenic Nocardia spp. are closely related biochemically and physiologically to mycobacteria, further studies are warranted.
Based on reports of chemical modification of the structure of rifampin and the resulting structure-activity relationships (17) , the following are considered the minimal structural requirements for rifamycin's activity: (i) two free hydroxyls at positions 21 and 23 of the ansa chain and (ii) the presence of a naphthoquinone ring carrying oxygen atoms at positions 1 and 8 in either the quinone or hydroquinone form (3). Of particular interest was a report that modifications of the ansa chain involving substitution or elimination of either 21-or 23-hydroxyls yielded inactive products (17) . The present study confirmed one of these hypotheses, specifically, that the 23-hydroxyl group is a prerequisite to the exhibition of rifampin's antimicrobial activity.
